{"name":"LENZ Therapeutics, Inc","slug":"lenz-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":19088000,"revenueGrowth":0,"grossMargin":0,"rdSpend":18670000,"netIncome":-82127000,"cash":25179000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Aceclidine ophthalmic solution","genericName":"Aceclidine ophthalmic solution","slug":"aceclidine-ophthalmic-solution","indication":"Presbyopia (age-related loss of accommodation)","status":"phase_3"},{"name":"Aceclidine+Brimonidine combination ophthalmic solution","genericName":"Aceclidine+Brimonidine combination ophthalmic solution","slug":"aceclidine-brimonidine-combination-ophthalmic-solution","indication":"Glaucoma or ocular hypertension (intraocular pressure reduction)","status":"phase_3"}]}],"pipeline":[{"name":"Aceclidine ophthalmic solution","genericName":"Aceclidine ophthalmic solution","slug":"aceclidine-ophthalmic-solution","phase":"phase_3","mechanism":"Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision.","indications":["Presbyopia (age-related loss of accommodation)","Potentially glaucoma or ocular hypertension"],"catalyst":""},{"name":"Aceclidine+Brimonidine combination ophthalmic solution","genericName":"Aceclidine+Brimonidine combination ophthalmic solution","slug":"aceclidine-brimonidine-combination-ophthalmic-solution","phase":"phase_3","mechanism":"This combination stimulates muscarinic receptors (via aceclidine) and alpha-2 adrenergic receptors (via brimonidine) to increase aqueous humor outflow and reduce intraocular pressure in the eye.","indications":["Glaucoma or ocular hypertension (intraocular pressure reduction)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"pipeline","source":"simplywall.st","summary":"Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers - simplywall.st","headline":"Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"pipeline","source":"simplywall.st","summary":"LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st","headline":"LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know","sentiment":"neutral"},{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNWFV2bHZHNzFmWUJpRE92akJRb1Q2bEVSWnB4YjRHX2lERTNROWthN0hJY0NaQzFTQTQyRy1vdFFaWVR1SlRVQmRrSGljUk9aVU44ZzVGeVhIeHNwYllwUm8wWTZ3Qm45OGVpc29pdnVXeF9DNjRnMnJGM0E3QTZNYnk5UGxUSEJ2RTNiS25teEl4aW5jcjdNR2ZJblc4ZkZfV2YxUzh0eDhLSWJnLWF4Z1hyV0R4dHNCRF9jVmRn?oc=5","date":"2026-02-23","type":"pipeline","source":"LENZ Therapeutics","summary":"LENZ Therapeutics to Present at Upcoming Investor Conferences - LENZ Therapeutics","headline":"LENZ Therapeutics to Present at Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNMndHSGFNN3JtYW1BWFpweHE3a29wZkFDV3EycXhrLUxjaE9NekJ6azNxNTlVbkl2UklfRGJ6RHU2MEU0QllQT2NKa1BMWEhnc2FOczFNNmMtc280MDF1YjNWSUhJRXNNb2FwU3NLb2l3RWxjQTBZNDBRR1dJTXljOVM1SS1ycDVOZnphc1JzWUxIQmxwTWlwc2dwQ3R6RENTZFpoOVFHa0ltbk5FemRxZWhvdjg3c1NLMnhfNXpHaw?oc=5","date":"2026-01-09","type":"earnings","source":"VisionMonday.com","summary":"LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch - VisionMonday.com","headline":"LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPREtjME9ERTd5UkhtY196aTJFR2R1ZGhvMUJXLVpzMXQ4R0R2ZUdOZDdCa1dqb2E2SjZHU0NqM2pSYkNVcGtpdmFfUTNLalNtTGhDZ203UHQ5TTdCd3c3US1BMzRhYWVkR1h4dkJjMHJqSHZLRDNvZHBXMU1QNEFwT2l1NTd2dFR0WFFWY3gzV0lNM28?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo Finance","summary":"Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before Long - Yahoo Finance","headline":"Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before Long","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxOUmhsbmg0TzF5NjJXbHctWWV1aEdfZVJMU3pyYmdQaEJncnhMSlgxaDhWSDJEempZQWxab0dHNldHd0hTQ2ppdHMwVjZqaEw2MENncTVGMThCTGxrOFNNLXhDamFnb0k2TkNJXzNYQ1NsMkVTTFQ0OVo3UHFDbk0zUUlaNWVMNndnZWlHMzN4eGxDQ0ZnMXNWVm9pQ1BLZ25BX2ptVHZXUXRtQmFXM296bUdKazMyUk1uMGlRY0R5QW9IcGdyRXB6TzJSaEhFZGZUaUZEWVN3UkMyYjZ2WHg2WldSbWhnVUxKelZobGRfMTZtQ1hVdExyamM4RXNFc0xuYVFJaw?oc=5","date":"2026-01-07","type":"earnings","source":"LENZ Therapeutics","summary":"LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates - LENZ Therapeutics","headline":"LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOSWhOTE8yaTVqTVJGWFZDeGJHb1Y1LUtyand4RC1ha0xZMUdFd05fb2p4cUVONlJfU0FoSDQ2bkRQeHQwYjlYUGcyYlladUFKR0NxeG9SdjV4aFBuWExLRVlObk5mbmVZRC1vbFpTRzlaMXprTHpzMnJkRTg4amtrZjd0dDE2ckJYSEYyeHRVRW42ZmhIeEFSN1JXclNILVh5Zm5kbVNjYnJZOTNaRUFHZmU3amZOMHNfcWU1TTBuRHV2UnpBSnZFNUVldFBCS0tyU1VPM1gtZlRvbnNrQ1U1WA?oc=5","date":"2025-12-01","type":"pipeline","source":"Quiver Quantitative","summary":"LENZ Therapeutics and Lotus Pharmaceutical Submit New Drug Application for VIZZ in South Korea to Treat Presbyopia - Quiver Quantitative","headline":"LENZ Therapeutics and Lotus Pharmaceutical Submit New Drug Application for VIZZ in South Korea to Treat Presbyopia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxQWXIxLWNaaUMtQl83d2QzcHJ2MmpmSDdJMXlWcUlYYWxOUFBfZXBzZ09MU21rYVY1MmZrUFNfcVZ5V3pQSnVuakgyR1Q5eVMxamFGV2k1U09ZWnZWSlZtVXphU2dHbEVIS0QzQ2otSkcyYUZUeldzczlyTTc1dXI2TkFlRlk0MnFnRUhNSW1wMlJ1UzhkMWVrcnFfZlRJLU9YNXdtcHBTMDNJMXNqMkdsR2UxaEcwVWpJN2pKMmpocXZ6U2hOa2RQdzFBZnRYQk15U1g3UHF1QkpPc05qY1cwTXI2ellEOGs1Z0phQVJqMDhrdERmMFZnd25NRWd3TkxFQUt5YWR3Z280UkhvSjJPd0hXOVdoMl9qVXc?oc=5","date":"2025-12-01","type":"pipeline","source":"LENZ Therapeutics","summary":"LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia - LENZ Therapeutics","headline":"LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxONWtNdnJNaTB0U3N4aG1iRXFrMnNlR05KMEkxRnlwcm1QbDR3ZFlmUzN6SmJYNWxPUE05MXB1Sko1SVFDa1dBS2NnZEZMTldBdUhWNGdXVmNPNnV5LVN4S0QtT0k0dFJuMkFYS0ZJcU16bFhobEljR2ljcFlNdU5DQkJ3RGdhYVBiVi1YXzVURWhJQUZtcDB3RTZjbU9kYWNYWjBKSUhBZFRyOFR2Skp3d0w0MHMxa0xzUXRvamlockNxTlNaTmoyR01XdTl2aUFZS2lYRGd3S29TcXhmUGdKZEE2N0RjU2Z0S2c?oc=5","date":"2025-11-05","type":"earnings","source":"LENZ Therapeutics","summary":"LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - LENZ Therapeutics","headline":"LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQdXd0MF8yUzl0WEIwNkl3Z3lIb1EzNV9RenlFcnB2UXRzR2U2RGZWOTNHamxEanhybExLVm5PV0VfbTNhZW5WU0thSno0NWtKbWs5NW91RFJMd1QwaV83Yldla1NiZGM1TUN3YVdJSV92QW1vM2RQUlVjNEdWWWpPa1NhVk84SGJZWlowTUZyWHFtUTBuSTc1REUxTHhxWGdzbDBpYnBB?oc=5","date":"2025-08-01","type":"regulatory","source":"Fierce Pharma","summary":"Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia - Fierce Pharma","headline":"Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQWFhrLWNBSWIzZ1dCVHRuMlZJclY0S3hXaDJLY0hxMTlNRTRmcXFPaFFjSVRYU1BLZ0dRM0t1bjdpQjMyR2k2SGQycTdPQVFXdE5YZzI4dkllaHNhR2E2SHFsbmRWWS1XV3JNT19wamY0YnlDc05BVllaWmJGZ0VMZC0tUDJ3SnhQN2JDUnhoeVNXQ1hjWVZaWjA1Ri1veDBGbmx4OGFHTURyalZ0LUxQeW90bGpJeTZKVmpVcFBGd0gwX2tIMWdDZ1hNbkhOel9hdHc?oc=5","date":"2025-07-08","type":"deal","source":"Ophthalmology Times","summary":"LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada - Ophthalmology Times","headline":"LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":19088000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":19088000,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18670000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-82127000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":25179000,"cashHistory":[],"totalAssets":305876000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}